): The program has the following objectives: To recruit innovative entry level as well as senior scientists into the lung cancer SPORE so as to enhance the overall translational research capability and bring new techniques and talent to our SPORE program to help these individuals develop the intellectual and technical skills required to be a productive investigator in lung cancer translational research; and to teach these individuals basic principles of cancer biology that are not commonly included in clinical training programs or Ph.D. degree programs. This program aspires to recruit and develop the careers of individuals who are: 1. Innovative and productive investigators trained in the principles of scientific methods, analysis of results, and biomedical communication; 2. Effective teachers who can articulate the principles of cancer biology and develop translational research programs based on a biological perspective of the disease; and 3. Clinical oncologists and basic scientists who can rapidly translate basic observations in cell and molecular biology into clinically applicable research programs and protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-05S9
Application #
6662774
Study Section
Project Start
2000-09-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Mender, Ilgen; LaRanger, Ryan; Luitel, Krishna et al. (2018) Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. Neoplasia 20:826-837
Gong, Ke; Guo, Gao; Gerber, David E et al. (2018) TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest 128:2500-2518
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835

Showing the most recent 10 out of 1059 publications